|
Landos Biopharma Inc (NASDAQ: LABP) |
|
Landos Biopharma Inc
LABP's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Landos Biopharma Inc 's sales fell
in the fourth quarter of 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Landos Biopharma Inc realized net income compared to net loss a year ago in fourth quarter of 2023
• More on LABP's Growth
|
|
Landos Biopharma Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 5.5 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.
• More on LABP's Valuation
|
|
|
|
|
Landos Biopharma Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 5.5 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.
Landos Biopharma Inc Price to Book Ratio is at 4.52 lower than Industry Avg. of 77.71. and higher than S&P 500 Avg. of 0.01
• More on LABP's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com